Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Tidmore

Rheumatology Valdosta, GA Medical Doctor

NPI 1073695292 CMS profile 3909

2418 N Oak St, Valdosta, GA 31602

Open in the dashboard

General payments

$3,031

155 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Tidmore of Valdosta, GA is reported in the CMS Open Payments database as having received $3,031 across 155 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 53rd percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $781 38
2024 General $1,115 54
2023 General $652 40
2022 General $128 3
2021 General $57 3
2020 General $195 12
2019 General $102 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Tidmore
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to William Tidmore were reported at $781. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year William Tidmore Rheumatology median Middle half National median
2019 $102 $744 $153–$2,687 $163
2020 $195 $462 $98–$2,027 $114
2021 $57 $531 $101–$2,153 $132
2022 $128 $627 $125–$2,303 $149
2023 $652 $741 $145–$2,524 $160
2024 $1,115 $830 $166–$2,660 $164
2025 $781 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $618 35 payments
  2. UCB, Inc. $296 20 payments
  3. Amgen Inc. $289 15 payments
  4. Pfizer Inc. $283 15 payments
  5. Novartis Pharmaceuticals Corporation $270 13 payments
  6. GlaxoSmithKline, LLC. $181 9 payments
  7. Genzyme Corporation $166 6 payments
  8. Aurinia Pharma U.S., Inc. $109 4 payments
  9. Radius Health, Inc. $107 5 payments
  10. AstraZeneca Pharmaceuticals LP $102 6 payments
  11. Other $608 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,849 151 payments
  2. Education $182 4 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $465 26 payments
  2. COSENTYX $250 12 payments
  3. XELJANZ $245 13 payments
  4. Cimzia $227 17 payments
  5. BENLYSTA $181 9 payments
  6. KEVZARA $166 6 payments
  7. LUPKYNIS $109 4 payments
  8. SKYRIZI $106 6 payments
  9. SAPHNELO $102 6 payments
  10. EVENITY $101 6 payments
  11. Other $1,412 68 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 158 drugs

Part D claims

10,609

Median for Rheumatology: 1,511

Drug cost

$7,046,079

Median for Rheumatology: $1,139,948

Branded share of claims

27.3%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 222 $1,696,575
Enbrel Sureclick Etanercept Brand 123 $942,471
Rinvoq Upadacitinib Brand 132 $881,279
Orencia Clickject Abatacept Brand 98 $562,114
Enbrel Mini Etanercept Brand 44 $330,565
Cosentyx Sensoready (2 Pens) Secukinumab Brand 39 $283,724
Enbrel Etanercept Brand 35 $257,920
Benlysta Belimumab Brand 46 $225,323
Humira(Cf) Adalimumab Brand 23 $210,819
Privigen Immun Glob G(Igg)/Pro/Iga 0-50 Brand 15 $157,702

The 10 drugs with the highest cost, of 158 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 176 billing codes

Paid by Medicare

$2,969,212

Of which drugs: $2,408,872

Medicare patients

1,591

Average age 74

Services billed

183,639

1,233 women, 358 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Osteoporosis 47%
Diabetes 31%
Chronic kidney disease 27%
Depression 24%
Ischemic heart disease 23%
COPD 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 421 44,640 $910,518
Injection, rituximab, 10 mg J9312 Office 22 7,400 $428,363
Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0129 Office 20 10,501 $352,637
Injection, golimumab, 1 mg, for intravenous use J1602 Office 18 17,650 $141,410
Injection, infliximab, excludes biosimilar, 10 mg J1745 Office 20 4,390 $108,478
Injection, romosozumab-aqqg, 1 mg J3111 Office 12 12,810 $108,320
Vaccine for influenza for injection into muscle 90662 Office 65 67 $5,272
Injection, zoledronic acid, 1 mg J3489 Office 33 165 $736
Injection, methylprednisolone acetate, 1 mg J1010 Office 65 4,920 $468
Injection, methylprednisolone sodium succinate, 5 mg J2919 Office 23 1,204 $273

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $228
$228 132 —
COSENTYX
  • Novartis Pharmaceuticals Corporation $135
$135 64 —
XELJANZ
  • PFIZER INC. $98
$98 22 —
KEVZARA
  • GENZYME CORPORATION $89
$89 16 —
BENLYSTA
  • GlaxoSmithKline, LLC. $88
$88 46 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

155 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record